20.09.2012 - The European VC firm Wellington Partners has announced the first closing of a fund exclusively dedicated to investments in EU life sciences companies.
Money for life science companies is coming back to Europe. After Edmond de Rothschild Investment Partners scored €125m for its fourth life sciences fund and Index Ventures announced to put €150m into life sciences companies, now, Wellington Partners (London, Zurich, Munich) has attracted commitments of over €70m for its new Wellington Partners IV Life Science Fund. With a target size of €120m, the venture capitalists expect it to be significantly larger than the previous Wellington Partners III Life Science Fund, which raised €78m. Investments will focus on European companies developing innovative medical devices, diagostics and biotechnology.
According to Wellington’s investment team, the new fund attracted investors from Germany, Switzerland, Austria, Benelux, France, the UK, the US and the Middle East, among them the European Investment Fund (EIF), LfA Förderbank Bayern, Austria Wirtschaftsservice GmbH and certain large family offices.
Dr. Rainer Strohmenger, General Partner at Wellington Partners, said that the closing was a "big success in a challenging financial environment". For investors who are willing to act anti-cyclically, the sector would „provide the opportunity to generate outstanding returns.“
Wellington Partners’ portfolio already comprises some successful European life sciences players, amongst them Swiss Actelion or German mtm laboratories, which was swallowed by Roche last year for up to €190m. Other players include: Cancer vaccine developer immatics, medtech company Invendo Medical, diagnostics specialist Oxford Immunotec, and heart valve developer Symetis.
27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.
20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.
19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.
18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.
13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.
12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.
07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.
06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.
04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.
JANUS® G3 Automation Workstations deliver real-time and future adaptability in throughput, capacity, and dynamic volume range from 0.5 μl to 5000 μl for consistent and reproducible sample preparation more